Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor VIII

Currently, no universally accepted definition of extended half‐life (EHL) recombinant FVIII (rFVIII) exists. Identifying the minimum half‐life extension ratio required for a reduction in dosing frequency compared with standard rFVIII could enable a more practical approach to decisions around prophylaxis with EHL rFVIII.

[1]  C. Hermans,et al.  Defining extended half‐life rFVIII—A critical review of the evidence , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  M. Tortorici,et al.  Population pharmacokinetics of recombinant coagulation factor VIII‐SingleChain in patients with severe hemophilia A , 2017, Journal of thrombosis and haemostasis : JTH.

[3]  I. Pabinger,et al.  Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII , 2017, Journal of thrombosis and haemostasis : JTH.

[4]  J. Oldenburg,et al.  European retrospective study of real‐life haemophilia treatment , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  P. Giangrande,et al.  Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[6]  J. Mahlangu,et al.  Extended half‐life clotting factor concentrates: results from published clinical trials , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  C. Négrier,et al.  Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  J. Oldenburg,et al.  A critical appraisal of one‐stage and chromogenic assays of factor VIII activity , 2016, Journal of thrombosis and haemostasis : JTH.

[9]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[10]  A. Iorio,et al.  Individualizing Factor Replacement Therapy in Severe Hemophilia , 2015, Seminars in Thrombosis & Hemostasis.

[11]  K. Steinitz,et al.  Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  L. Valentino,et al.  Individualizing prophylaxis in hemophilia: a review , 2015, Expert review of hematology.

[13]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[14]  E. Berntorp,et al.  Methods for individualising factor VIII dosing in prophylaxis , 2014, European journal of haematology. Supplementum.

[15]  M. Reding,et al.  Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A , 2014, Journal of thrombosis and haemostasis : JTH.

[16]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[17]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[18]  D. Viuff,et al.  Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A , 2013, Journal of thrombosis and haemostasis : JTH.

[19]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  M. Skinner.  WFH: Closing the global gap – achieving optimal care , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[22]  G. Spotts,et al.  Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. , 2012, Blood.

[23]  A. Neff,et al.  Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  M. Morfini,et al.  Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[26]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[27]  P. Mannucci,et al.  A multicenter pharmacokinetic study of the B‐domain deleted recombinant factor VIII concentrate using different assays and standards , 2003, Journal of thrombosis and haemostasis : JTH.

[28]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[29]  M. Carcao,et al.  Factor VIII/factor IX prophylaxis for severe hemophilia. , 2016, Seminars in hematology.

[30]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[31]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.